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Abstract
Background: [
18F]FAZA is a PET biomarker with great potential for imaging tumor hypoxia. Aim of our study was
to compare [
18F]FAZA uptake in mice with subcutaneous exogenous CT26 colon carcinomas and endogenous
polyoma middle-T (PyV-mT) mammary carcinomas and to analyze the influence of different breathing protocols in
CT26 colon carcinomas as well as the reversibility or irreversibility of [
18F]FAZA uptake.
Methods: We injected subcutaneous CT26 colon carcinoma or polyomavirus middle-T (PyV-mT) mammary
carcinoma-bearing mice intravenously with
18F-FAZA and performed PET scans 1-3 h post injection (p.i.). To analyze
the impact of oxygen supply in CT26 carcinomas we used three different breathing protocols: (P0) air; (P1) 100%
oxygen 1 h prior injection until 3 h p.i.; (P2) 100% oxygen breathing starting 2 min prior tracer injection until 1 h p.
i. and during the PET scans; mice were breathing air between the 2 h and 3 h 10 min static scans. Normalized PET
images were analyzed by using defined regions of interest. Finally, some mice were dissected for pimonidazole
immunohistochemistry.
Results: There was no difference in
18F-FAZA uptake 1-3 h p.i. between the two carcinoma types (CT26: 1.58 ±
0.45%ID/cc; PyV-mT: 1.47 ± 0.89%ID/cc, 1 h p.i., tumor size < 0.5 cm
3). We measured a significant tracer clearance,
which was more pronounced in muscle tissue (P0). The [
18F]FAZA tumor-to-muscle-ratios in CT26 colon carcinoma-
bearing mice 2 h and 3 h, but not 1 h p.i. were significantly higher when the mice breathed air (P0: 3.56 ± 0.55, 3
h) compared to the oxygen breathing protocols (P1: 2.45 ± 0.58; P2: 2.77 ± 0.42, 3 h). Surprisingly, the breathing
protocols P1 and P2 showed no significant differences in T/M ratios, thus indicating that the crucial [
18F]FAZA
uptake phase is during the first hour after [
18F]FAZA injection. Importantly, the muscle clearance was not affected
by the different oxygen breathing conditions while the tumor clearance was lower when mice were breathing air.
Conclusion: Exogenous CT26 colon carcinomas and endogenous polyoma middle-T (PyV-mT) mammary
carcinomas showed no differences in [
18F]FAZA uptake 1-3 h p.i. Our analysis using various breathing protocols
with air (P0) and with pure oxygen (P1, P2) clearly indicate that [
18F]FAZA is an appropriate PET biomarker for in
vivo analysis of hypoxia revealing an enhanced tracer uptake in tumors with reduced oxygen supply. [
18F]FAZA
uptake was independent of tumor-type.
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Tumor hypoxia, one of the major hallmarks of malig-
nant tumor disease, is indicative of more aggressive
tumor progression and is associated with angiogenesis
and metastasis [1-4]. Hypoxic tumor tissue is also
known to be more resistant to radiotherapy and che-
motherapy compared to normally oxygenated tumor tis-
sue [1]. Identifying and targeting the hypoxic areas of
tumors is pivotal for selecting patients who require addi-
tional or more specific treatment strategies. Several
invasive and noninvasive techniques are currently avail-
able, although oxygen electrode systems for detecting
hypoxia are not clinically used due to their invasiveness
and limitations concerning the accessibility of the tumor
[5,6]. However, noninvasive in vivo identification and
quantification of hypoxic tumor regions using positron
emission tomography (PET) is a field of growing interest
and has been investigated in recent years [7,8]. Cur-
rently, a variety of PET tracers are available for hypoxia
imaging, such as [
18F]fluoromisonidazole ([
18F]FMISO)
[9-13], [
18F]FAZA [14-16], [
124I]-iodo-azomycinarabino-
furanoside ([
124I]IAZA) [17,18] and [
64Cu]-(II)diacetyl-
bis(N4-methylthiosemicarbazone) ([
64Cu]ATSM)
[19-21]. The 2-Nitroimidazole tracers show selective
uptake in hypoxic cells both in vitro and in vivo. In con-
trast [
64Cu]ATSM binding may also involve mechanisms
independent of hypoxia [22]. In line with this Yuan et
al. have recently reported that [
64Cu]ATSM is a valid
hypoxia marker for some tumors but not for all as
enhanced tracer uptake was found also in areas without
any hypoxia but with enhanced perfusion [23].
However, for reliable use of 2-Nitroimidazole tracers
in clinical settings, further evaluation studies are needed.
[
18F]FAZA and [
18F]FMISO are currently two of the
PET biomarkers with great promise for imaging tumor
hypoxia [24] and have been the focus of clinical studies.
2-Nitroimidazole tracers such as [
18F]FAZA are readily
diffusible through cell membranes and undergo reversi-
ble reduction by intracellular reductases to yield nitroi-
midazole radical anions, which are then rapidly
reoxidized to neutral molecules that diffuse out of the
c e l l .I ft h ec o n c e n t r a t i o no fo x y g e ni nt u m o rt i s s u ei s
low, oxidation competes with the irreversible binding of
the radical anion to other substrates, which forms irre-
versible compounds with cellular macromolecular com-
ponents. Therefore, with decreasing intracellular
concentration of oxygen the tracer accumulates within
the hypoxic tissue. Piert et al. proved the principle of
the particular trapping mechanism in a porcine hypoxic
liver model by applying extensive in vivo and ex vivo
analyses that revealed a direct influence of the oxygen
concentration on tracer accumulation [9,25]. An alterna-
tive approach to proving the dependence of hypoxia
tracer accumulation on the oxygen concentration is the
change of breathing air or oxygen by employing differ-
ent breathing protocols. The inverse correlation between
[
18F]FMISO and [
18F]FAZA uptake and tumor tissue
oxygenation has been shown in our previous studies
[14]. According to Piert et al., [
18F]FAZA does not show
intertumoral differences in total tumor uptake as evalu-
ated by biodistribution in three different xenograft
mouse tumor-models [14]. However, there has not been
a study that has investigated the dependency of tracer
uptake on different breathing protocols with various
oxygen incubation times. Thus, in the present study, we
focused on the further evaluation of [
18F]FAZA using an
exogenous and an endogenous tumor model with three
different breathing protocols and compared the results
with in vivo [
18F]FDG-scans and ex vivo pimonidazole
immunohistochemical analyses of the tumors. Impor-
tantly, because clinical observations in patients suggest a
reversible binding of [
18F]FAZA [26], we also focused
on this particular issue in a preclinical experiment and
analyzed the reversibility of [
18F]FAZA binding in
hypoxic tumor tissue and normoxic muscle tissue using
different oxygen breathing protocols.
Materials and methods
Tracer synthesis
For a detailed description of all tracer synthesis please
see Additional file 1.
Animal models
C57BL/6 mice expressing the polyomavirus middle T
(PyV-mT) antigen under the control of the mammary-
specific mouse mammary tumor virus long terminal
repeat promoter (MMTV-LTR) [27,28], were kindly pro-
vided by Lesley G Ellies, from the School of Medicine at
the University of California at San Diego (La Jolla, USA)
and were bred at the animal care facilities at the Univer-
sity of Tübingen. For imaging experiments, transgenic
PyV-mT C57BL/6 mice were grown to 18 weeks of age.
At this age, the spontaneous mammary tumors reached
av o l u m eo f0 . 9 8 2±0 . 9 5 8c m
3 (n = 20). On average,
each mouse had 5 tumors along the mammary glands
[27,28].
BALB/c mice were purchased from Charles River
Laboratories and were between 8 and 10 weeks of age.
CT26 mouse colon carcinoma cells were kindly provided
by Prof. Dr. med. Ralph Mocicat (Institute of molecular
immunology, German Research Center for Environmen-
tal Health, Munich, Germany) and analyzed for myco-
plasma infection once per month. For CT26 mouse
colon carcinoma cell culture please see Additional file 1.
CT26 cells (10
6 in 200 μL phosphate-buffered saline;
PBS [29,30]) were subcutaneously injected in the right
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tumor inoculation, the tumors reached a volume of
0.279 ± 0.086 cm
3 (n = 10).
All animal experiments were performed according to
the current guidelines for the care and use of research
animals under the German Animal Protection Law. Ani-
mal experiments were approved by the local government
(Regierungspräsidium Tübingen).
In vivo PET imaging studies
PET studies investigating the tumor type-dependent
uptake of [
18F]FAZA were conducted with PyV-mT
C57/BL6 mice (n = 9 mice, n = 20 tumors) and CT26
tumor-bearing BALB/c mice (n = 10 mice, n = 10
tumors). Under isoflurane anesthesia, the tail veins of
the mice were injected with 14.2 ± 0.5 MBq [
18F]FDG
or 12.3 ± 1.0 MBq [
18F]FAZA on two consecutive days.
[
18F]FDG scans were performed to identify large necro-
tic tumor regions in mice with large PyV-mT mammary
carcinomas (> 1.5 cm
3)t h a tw e r es u b s e q u e n t l yi g n o r e d
during [
18F]FAZA PET image analysis. In addition we
performed [
18F]FDG PET scans in some CT26 colon
carcinoma bearing mice and could not detect large
necrotic areas. For [
18F ] F D G ,a1hu p t a k et i m ew a s
allowed prior to a 10 min static scan. Mice were kept
under 1.5% isoflurane anesthesia with an air flow rate of
0.6 L/min using a dedicated vaporizer (Vetland, Louis-
ville, KY, USA) for the entire uptake and scan time. The
body temperature of mice was maintained at 37°C on
the scanner bed and in the incubation chambers by
using heating pads. During the [
18F]FAZA uptake time,
mice were kept conscious in room air. The main study
was performed using static PET scan protocols
described in the next section (breathing protocols).
However, prior to onset of our study we performed
antecedent dynamic studies to ensure that the static
PET scans are performed during the transient [
18F]
FAZA-equilibrium phase. Static 10 min duration PET-
scans were performed at 1 h, 2 h and 3 h p.i. using an
Inveon-dedicated PET scanner (Siemens Healthcare,
Knoxville, TN, USA) with an axial field of view of 12.7
cm and a spatial resolution of 1.4 mm (full width at half
maximum, FWHM) [31]. After the last [
18F]FAZA PET
scan, the animals were sacrificed and the tumors were
harvested for ex vivo analysis.
Breathing protocols
To prove the principle of hypoxia detection using [
18F]
FAZA, we investigated the specific uptake in CT26
colon carcinoma-bearing BALB/c mice when the mice
breathed normal air with 21% (P0)) or 100% oxygen
(P1); we expected a lower [
18F]FAZA uptake when
breathing 100% oxygen as a consequence of an
enhanced systemic oxygen supply. To obtain more
information about the importance of air or 100% oxygen
breathing on [
18F]FAZA uptake during the preincuba-
tion time and the first hour after [
18F]FAZA administra-
tion, we designed a third protocol in which mice
breathed 100% oxygen 2 minutes prior and 1 h after
[
18F]FAZA administration (P2). Moreover, we analyzed
the role of air breathing in between the PET scans (P1
vs. P2).
Breathing protocols were as follows (Figure 1A):
￿ P0: room air during the entire procedure (n = 10;
21% oxygen);
￿ P1: 100% oxygen 1 h prior to tracer injection and
during the entire scan time (n = 7);
￿ P2: 100% oxygen 2 min prior to tracer injection, 1
h p.i. and during the scans, which were performed at
2ha n d3hp.i. T h em i c eb r e a t h e dr o o ma i r
between the scans (n = 7).
Mice were kept in a chamber under 100% oxygen at a
flow rate of 0.6 L/min without anesthesia during the
pre-injection time (P1, P2) and during the uptake phase
after the injection. During the scans, the animals were
placed in a custom-made chamber on the scanner bed
(Figure 1B). Mice were kept conscious except during
tracer injection (1 min) and PET scans (10 min). Again,
[
18F]FDG scans were preemptively performed to confirm
the viability of the tumor tissue. We divided the CT26
colon carcinoma-bearing mice into two groups as CT26
colon carcinomas reach an exponential growth phase at
day 12 to 14 after CT26 cell inoculation which, in turn,
would cause a higher heterogeneity of the tumors, as
the larger CT26 tumors showed a tendency toward
higher [
18F]FAZA uptake (Table 1). The first group (n =
4) was scanned under the P0 protocol and on the subse-
quent day under the P1 protocol; the second group (n =
3) was scanned under the P0 and P2 protocols. In addi-
tion, we scanned mice individually using the breathing
p r o t o c o l sP 0( n=6 ) ,P 1( n=3 )a n dP 2( n=4 )t o
obtain at least seven mice per breathing protocol group
(P0, P1 and P2) for analysis.
PET data analysis
PET data were reconstructed using an OSEM 2D algo-
rithm into a 128 × 128 image matrix (resulting in a final
voxel size of 0.79 × 0.79 × 0.8 mm
3). After correction for
decay, the data were analyzed by drawing standardized
volumes of interest (VOIs). In the transverse image
planes, a circular region of interest (ROI) of 4.8 mm in
diameter was placed over the maximum activity in the
tumor, and two ROIs of 3.2 mm in diameter were placed
over the slices directly above and below the slice of maxi-
mum activity. In this way, it could be ensured that
regions outside the tumors as well as large necrotic areas
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3 were not included in
the analysis VOI. Furthermore, we expected a “dilution
effect” i fa l lt u m o rr e g i o n s-h y p o x i ca sw e l la sn o n -
hypoxic areas - were included in the analysis. The
shoulder muscle (biceps) of the left forelimb was used as
a reference region. The size of the muscle was confirmed
by a mouse anatomy atlas [32]. [
18F]FDG scans supported
the VOI definition, as the dimension of the muscle was
clearly visible. Two ROIs of 5 mm in diameter were
placed over two slices in the muscle. Image analysis was
performed with the microPET ASIPro VM software pack-
age (Siemens Healthcare, Knoxville, TN, USA). The slice
with the highest radioactivity concentration in the tumor
was identified visually and with the navigation function of
the software, which identified the pixel with the highest
intensity. Quantitative PET data were reported as the per-
centage of the injected dose per cm
3 (%ID/cc) or as the
tumor-to-muscle ratio (T/M).
Figure 1 Breathing protocols with increasing oxygen incubation times. A, to analyze the impact of oxygen supply in CT26 carcinomas we
used three different breathing protocols: (P0) air; (P1) 100% oxygen 1 h prior injection until 3 h p.i.; (P2) 100% oxygen breathing starting 2 min
prior tracer injection until 1 h p.i. and during the PET scans; mice were breathing air between the 2 h and 3 h 10 min static scans. The flow
chart indicates the injection time points (Inj.) and the PET scans (PET) relative to the uptake times and oxygen or air breathing protocols. B,
custom-made chamber for the microPET scans. Animals were anesthetized with 1.5% isoflurane and 0.6 L/min carrier gas flow during injection
and microPET scans (either air or 100% oxygen, depending on the breathing protocol).
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For the assessment of tumor hypoxia, pimonidazole (60
mg/kg, Chemicon International, Temecula, CA, USA)
was injected in some CT26 colon carcinoma bearing
mice intraperitoneally 1 h before the mice were sacri-
ficed. Tumors were fixed in 4% formalin, embedded in
paraffin and cut into 5 μm slices with a manual rotary
microtome (RM2235; Leica, Nussloch, Germany). Slices
were analyzed using the Hypoxyprobe™-1 Kit for the
detection of tissue hypoxia (Chemicon International,
Temecula, CA, USA) with a confocal microscope (DM
5000B, Leica, Wetzlar, Germany) and FITC-fluorescence
(primary antibody: Hypoxyprobe-1Mab1). A control
stain was performed with PBS instead of the primary
antibody. Hematoxylin and eosin (H&E) stains were per-
formed on subsequent slices according to standard pro-
cedures [33].
Statistics
Differences in [
18F]FAZA tumor type-dependent uptake
were compared using a two-sample Student’s t-test. Dif-
ferences in [
18F]FAZA uptake according to the breathing
protocol were analyzed using the Wilcoxon test and the
JMP software package (SAS Institute Inc, Cary, NC,
USA). Data were represented as the mean ± standard
deviation (SD). A value for p < 0.05 was considered to
be statistically significant, and a value for p < 0.01 was
highly statistically significant.
Results
Evaluation of tumor type-dependent [
18F]FAZA uptake
PyV-mT mammary carcinoma and CT26 colon carci-
noma-bearing mice were imaged 1 h, 2 h and 3 h after
injection of 12.3 ± 1.0 MBq [
18F]FAZA using breathing
protocol P0 (Figure 1A and 1B; P0 breathing protocol).
Absolute tracer uptake decreased in the PyV-mT mam-
mary carcinomas from 1.31 ± 0.71 %ID/cc at 1 h to 0.92
± 0.61 %ID/cc at 3 h and decreased in the CT26 colon
carcinomas from 1.53 ± 0.43 %ID/cc at 1 h to 0.84 ±
0.26 %ID/cc at 3 h (Figure 2, Table 1). Absolute tracer
uptake in muscle tissue in both mouse strains (C57BL/6,
BALB/c) decreased much more pronounced than in
carcinomas. No statistically significant differences in
[
18F]FAZA uptake were found between the endogenous
PyV-mT mammary carcinomas and the exogenous sub-
cutaneous CT26 colon carcinomas (p = 0.29; Figure 2,
Table 1). Figure 3 represents the dynamics of the [
18F]
FAZA uptake in a CT26 colon carcinoma-bearing
mouse over 3 h (breathing protocol P0), indicating that
the peak uptake was achieved 20 min post injection (p.
i.), whereas the T/M is highest at 3 h p.i.
The [
18F]FAZA-PET data from PyV-mT mammary
carcinomas and CT26 colon carcinomas were further
analyzed according to tumor sizes (Table 1). Endogen-
ous PyV-mT mammary carcinomas were classified into
three groups: 1) tumors that were smaller than 0.5 cm
3;
2) tumors that were between 0.5 cm
3 and 1.5 cm
3 and
3) tumors that were larger than 1.5 cm
3. Statistical ana-
lysis did not reveal any significant differences at any
scan time between small, medium sized, and large PyV-
mT mammary carcinomas. Similar to the PyV-mT
mammary carcinomas, the CT26 colon carcinomas were
classified into tumor lesions that were smaller than 0.15
cm
3 and tumor lesions that were between 0.15 cm
3 and
0.5 cm
3. Similar to the PyV-mT mammary carcinomas,
we did not observe any significant differences in [
18F]
FAZA uptake between the small and medium sized
CT26 colon carcinomas. However, in the CT26 tumor
model, there was a tendency toward a higher tumor
uptake with increasing tumor size, which is in contrast
to the PyV-mT model in which the opposite effect was
observed (Table 1).
Investigations of the [
18F]FAZA clearance revealed a
significant relative clearance of 40 ± 15% in the endo-
genous PyV-mT mammary carcinomas (mice: n = 9,
tumors: n = 20) and a similar significant relative clear-
ance of 39 ± 12% in the exogenous CT26 colon carcino-
mas (n = 10) 3 h after tracer injection (p < 0.01
compared to %ID/cc 1 h after injection, Figure 4). The
[
18F]FAZA clearance was significantly higher in the
muscle tissue of the PyV-mT mammary carcinoma (73
± 6%; C57BL/6) and the CT26 colon carcinoma-bearing
mice (72 ± 5%; BALB/c) compared to the mammary and
colon carcinomas (Figure 4, p < 0.01). Importantly, both
Table 1 Tumor type and size-dependency of [
18F]FAZA in CT26 colon carcinomas and PyV-mT mammary carcinomas
Tumor Tumor size 1 h p.i. 2hp.i. 3hp.i.
PyV-mT (n = 20) 0.982 ± 0.958 cm
3 1.31 ± 0.71 1.06 ± 0.69 0.92 ± 0.61
CT26 (n = 10) 0.279 ± 0.086 cm
3 1.53 ± 0.43 1.14 ± 0.37 0.84 ± 0.26
PyV-mT (n = 12) 0.15 - 0.50 cm
3 1.47 ± 0.89 1.13 ± 0.83 0.97 ± 0.70
PyV-mT (n = 4) 0.5 - 1.5 cm
3 1.22 ± 0.59 1.05 ± 0.61 0.91 ± 0.56
PyV-mT (n = 4) > 1.5 cm
3 1.15 ± 0.41 0.86 ± 0.36 0.76 ± 0.42
CT26 (n = 4) < 0.15 cm
3 1.37 ± 0.41 0.92 ± 0.38 0.68 ± 0.38
CT26 (n = 6) 0.15 - 0.50 cm
3 1.58 ± 0.45 1.22 ± 0.35 0.90 ± 0.22
Data are presented as %ID/cc ± SD. h: hour, p.i.: post injection. PyV-mT n = 9 mice, n = 20 tumors.
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0.90). The rapid clearance from the non-hypoxic muscle
tissue compared to the hypoxic tumor tissue explains
the improved detectability of hypoxic tumor tissue at
later scan time points (Figure 2, Figure 4).
To exclude necrotic areas in the CT26 colon carcino-
mas, we also performed [
18F]FDG scans on some of the
mice. Importantly, we did not identify any impaired
[
18F]FDG uptake in the CT26 colon carcinomas, which
is a sign of necrosis (Figure 5A). This was further con-
firmed by H&E staining of the slices of the CT26 colon
carcinomas, which displayed no signs of necrotic tumor
tissue (Figure 5B). The correlation between in vivo [
18F]
FAZA scans (Figure 5C) and ex vivo pimonidazole immu-
nohistochemistry staining of the hypoxic areas in slices of
CT26 colon carcinomas (Figure 5D) further confirmed
the specificity of [
18F]FAZA to hypoxic tumor tissue.
Oxygen incubation time-dependent [
18F]FAZA tumor
uptake
We analyzed the role of oxygen breathing during the
preincubation time (2 min vs. 1 h) and during the first
hour after [
18F]FAZA-injection using three different
breathing protocols with different air or 100% oxygen
incubation times (Figure 1A) in the CT26 colon carci-
noma-bearing mice. Moreover, we analyzed the role of
air breathing between the 1 h, 2 h, and 3 h PET scans
(P1, P2). During the scans, the animals were placed in a
custom-made chamber on the scanner bed (Figure 1B).
Tumor-to-muscle ratios of [
18F]FAZA 2 h and 3 h p.i.
were significantly higher (p < 0.01) when the mice
breathed air (3.56 ± 0.55; P0) compared to the oxygen
breathing protocols P1 (2.45 ± 0.58; 100% oxygen 1 h
prior tracer injection and during the entire scan time)
and P2 (2.77 ± 0.42; partly 100% oxygen breathing; Fig-
u r e6 A ) ,p r o v i n gt h ep r i n c i p l eo fh y p o x i ad e t e c t i o n .
Interestingly, we observed no differences in tumor-to-
muscle ratios 1 h after [
18F]FAZA-injection when the
mice breathed room air (P0) or 100% oxygen (P1).
1h p.i. 2h p.i. 3h p.i.
time
Figure 2 [
18F]FAZA tumor and muscle uptake in both tumor
models. The [
18F]FAZA muscle clearance is clearly more
pronounced compared to tumor clearance (** p < 0.01; PyV-mT
C57/BL6, n = 9; CT26 colon carcinoma-bearing BALB/c, n = 10).
Note that there is no difference in between the two animal models
in terms of tracer clearance from both tumor and muscle tissue
(breathing protocol P0, air).
min
20 60 120 180
Figure 3 Dynamic [
18F]FAZA-PET scan.[
18F]FAZA-uptake in a CT26
colon carcinoma over 3 h using breathing protocol P0 (see also
Figure 1A). Note that the peak uptake is achieved 20 minutes p.i.
** **
p
.
i
.
Figure 4 [
18F]FAZA tumor and muscle clearance in both tumor
models.[
18F]FAZA clearance is displayed in both animal models
(relative to 1 h after injection) with a higher muscle clearance (** p
< 0.01; PyV-mT C57/BL6, n = 9; CT26 colon carcinoma-bearing
BALB/c, n = 10).
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in the tumor-to-muscle ratios between the oxygen
breathing protocols P1 and P2 (Figure 6A). Because the
mice breathed 100% oxygen 60 minutes after [
18F]
FAZA- injection (until the first PET scan) in both pro-
tocols (P1 and P2), it seems that the duration of 100%
oxygen breathing (2 min vs. 1 h) prior to the [
18F]
FAZA- injection does not significantly influence the
results for both early and late PET scans. Figure 6B dis-
plays representative [
18F]FAZA-PET images of the CT26
colon carcinoma-bearing mice under the P0, P1, and P2
breathing protocols 1 h, 2 h, and 3 h after [
18F]FAZA-
injection. Interestingly, the muscle clearance was unaf-
fected by the different oxygen breathing conditions and
remained at 72 ± 5% for P0, 71 ± 10% for P1 and 71 ±
7% for P2 (Figure 6C). However, the rate of tumor clear-
ance was significantly lower when the mice breathed
room air (P0; 39 ± 12%) compared to when they
breathed 4 h of pure oxygen (P1; 53 ± 14%; p < 0.05).
In contrast, the P2 breathing protocol resulted in a very
heterogeneous tumor [
18F]FAZA clearance of 32 ± 23%
(Figure 6C).
Discussion
A variety of PET tracers for noninvasive tumor hypoxia
imaging are currently available [9-21,24-26]. The lack of
sufficient in vivo evaluation makes judgments about the
predictive value of these traces in the detection of
hypoxic tumor regions difficult. However, various
reports have demonstrated that [
18F]FAZA, compared to
[
18F]FMISO, is a valid hypoxia imaging agent [14-16].
Furthermore, [
18F]FAZA has been shown to be superior
in comparison to [
124I]IAZA. In a study by Reischl et al.
[
124I]IAZA displayed no improvement in tumor to mus-
cle ratios although the tracer uptake could be followed
for up to 48 h after injection. This could be either
related to a loss of
124I or a hint for reversibility of the
uptake mechanism [17]. Piert et al. further reported that
[
18F]FAZA did not show intertumoral differences in
terms of total tumor uptake in 3 different xenograft
control – no antibody pimonidazole antibody
H&E
B
E D
500 µm
3 mm 500 µm
18F]FDG
A C
[
18F]FAZA [
Figure 5 Comparison of in vivo [
18F]FAZA- and [
18F]FDG images and pimonidazole immunohistochemistry of the same tumor. A and C,
Typical sample of [
18F]FDG- and [
18F]FAZA-PET images of a CT26 colon carcinoma (tumor size category: 0.15-0.5 cm
3). B, ex vivo analysis of the
same CT26 colon carcinoma (A and C) by H&E staining of tumor slices. Red squares in A and C indicate the H&E-stained tumor region. D and E,
ex vivo pimonidazole immunohistochemistry of the areas indicated in A and C. The mice were injected with 60 mg/kg pimonidazole 1 h prior to
ex vivo analysis. Tumor slices were analyzed using the Hypoxyprobe™-1 kit for the detection of tissue hypoxia. Control staining was performed
with PBS instead of the primary antibody.
Maier et al. Radiation Oncology 2011, 6:165
http://www.ro-journal.com/content/6/1/165
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lack of endogenous tumor models in that study, and the
above-mentioned conclusions were only based on post
mortem biodistribution results. We have chosen these
two tumor-types to study an endogenous (PyV-mT
mammary carcinoma) and an exogenous carcinoma
model (CT26 colon carcinoma) to identify potential dif-
ferences between the uptake patterns in exogenous and
endogenous carcinomas. Our study reveals that [
18F]
FAZA displays no difference in uptake between the exo-
genous (CT26) and the endogenous (PyV-mT) mouse
tumor model. Furthermore, there was no connection
between uptake and tumor size when using [
18F]FAZA
although our data show that there is a tendency toward
higher uptake in larger tumors in the CT26 model,
whereas we observed the opposite effect in the PyV-mT
model (Table 1). Small lesions were difficult to detect in
PyV-mT mice along the mammary glands, whereas
small tumors (< 0.15 cm
3) were clearly identifiable in
the CT26 mice. Lipophilicity and plasma half-life are
fundamental attributes that influence tumor-to-back-
ground ratios and total uptake. [
18F]FAZA has a high
potential for rapid diffusion into hypoxic tissue and fast
clearance from non-hypoxic tissue compared to other
hypoxia tracers, such as [
18F]FMISO [14]. [
18F]FAZA
indeed displayed a substantial clearance from the tumor
and muscle tissue, with a significantly faster and more
substantial clearance from the muscle, which provides
more evidence that the trapping in hypoxic cells is
reversible (Figure 2). Busk et al. showed in a mouse
study that hypoxic squamous cell carcinomas of the cer-
vix display a washout type [
18F]FAZA-TAC [34]. The
authors hypothesize that the observed washout could be
due to the rapid tracer clearance in mice, which may be
P0
P1
P2
A B
C
1h p.i. 2h p.i. 3h p.i.
1h p.i. 2h p.i. 3h p.i.
p
.
i
.
Figure 6 Assessment of [
18F]FAZA tumor-to-muscle ratios in CT26 colon carcinomas under different breathing protocols.A ,w eu s e d
three different breathing protocols: (P0) air; (P1) 100% oxygen 1 h prior injection until 3 h p.i.; (P2) 100% oxygen breathing starting 2 min prior
tracer injection until 1 h p.i. and during the PET scans; mice were breathing air between the 2 h and 3 h 10 min static scans. B, an example of
microPET images of CT26 colon carcinoma-bearing mice (arrowheads indicate tumors). Images were taken 1 h, 2 h and 3 h after injection of
[
18F]FAZA following the P0, P1 and P2 protocols. C, [
18F]FAZA clearance (relative to 1 h after injection) from tumor and muscle tissue with a clear
oxygen dependency (* p < 0.05; ** p < 0.01; P0: n = 10, P1: n = 7, P2: n = 7).
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tissue image contrast than the rate of specific binding
[34]. However, there are also in vitro as well as clinical
data suggesting that compounds incorporating a 2-
nitroimidazole as functional unit are characterized by a
reversible uptake in tumors [26,35]. Moreover Busk et
al. showed an evident loss of [
18F]FAZA in different
tumor cell lines in vitro [35], while Shi et al. recom-
mend in a study focusing on patients with head and
neck cancer to favour a reversible 2-compartmental
model [26]. Consequently the reversible uptake in carci-
nomas represents a major drawback of [
18F]FAZA as
the image contrast is affected by the perfusion and the
vascular architecture.
In our study, we found that the clearance from muscle
tissue was unaffected by the different breathing protocols,
whereas the tumor clearance showed a tendency toward
higher clearances with longer oxygen incubation times
(Figure 6). This contrasts with the findings from Reischl
et al. who reported that the reduced T/M ratio under
carbogen (95% oxygen, 5% CO2) breathing was related to
a reduced muscle washout whereas the tumor clearance
remained unchanged [17]. On the other hand, Mortensen
et al. observed in mammary carcinoma bearing carbogen
breathing mice primarily lower [
18F]FAZA tumor to
blood ratios compared to air breathing mice [36].
Furthermore, the muscle tissue was not affected by the
different breathing protocols, as was the case for the
tumor tissue; this also illustrate the specificity of [
18F]
FAZA for hypoxic tumor tissue. A potential benefit of
nitroimidazoles such as [
18F]FAZA might be the under-
lying bioreductive mechanism in hypoxic cells. [
18F]
FAZA is mainly reduced by cytosolic xanthine oxidase
upon entering the hypoxic cell and is only reduced to a
small extent by the mitochondrial respiratory chain
complex I [20]. Thus, it follows that the reduction of
[
18F]FAZA is not dependent upon NADH levels (or the
“redox-state” of the cell) but is directly linked to the
intracellular oxygen level. This is also true for other
nitroimidazoles.
To our knowledge, this is the first study to correlate
[
18F]FAZA tumor uptake with different oxygen breath-
ing protocols (P0, P1, P2) to determine the cell oxygen
level-dependent uptake of [
18F]FAZA as other investiga-
tors (Piert et al. and Reischl et al.) analyzed exclusively
littermates that breathed air or 95% oxygen with 5%
CO2 [14]. The tumor-to-muscle ratios of [
18F]FAZA at
2 h and 3 h p.i. were higher using the P0 breathing pro-
tocol (21% oxygen) compared to the P1 and P2 oxygen
breathing protocols. [
18F]FAZA tumor uptake showed
an inverse correlation with oxygen supply, which con-
firms the specificity for hypoxia detection (Figure 6).
Surprisingly, the P0 breathing protocol and the P1 and
P2 oxygen breathing protocols did not show significant
differences in the T/M ratios 1 h post [
18F]FAZA-
injection.
Subsequently, the similar tracer uptake in tumors in
the P1 and P2 breathing protocols during the investiga-
tions 2-3 h p.i. clearly indicate that the crucial uptake
phase for [
18F]FAZA occurs during the first hour after
injection because air breathing in between the 1 h, 2 h
and 3 h PET scans (P2) did not significantly impair [
18F]
FAZA uptake compared to the oxygen breathing proto-
col (P1). Sequential [
18F]FDG (Figure 5A) and [
18F]
FAZA (Figure 5C) scans followed by ex vivo H&E (Fig-
ure 5B) and pimonidazole immunostaining (Figure 5D
and 5E) strongly support the feasibility of [
18F]FAZA in
terms of tumor hypoxia imaging.
Conclusion
We could not detect any difference in [
18F]FAZA uptake
regarding the two tumor types and the tumor size. The
uptake and clearance of [
18F]FAZA in carcinomas was
dependent on the oxygen supply, especially during the
time prior to and until 1 h after [
18F]FAZA-injection,
whereas the uptake and clearance of [
18F]FAZA in mus-
cle tissue was not affected by different oxygen breathing
protocols. The different oxygen breathing protocols
clearly indicate that [
18F]FAZA is a valid marker for
hypoxia because higher tracer uptake in tumors corre-
lates with decreased oxygen supply. The critical time for
[
18F]FAZA uptake is the first hour after tracer injection,
whereas the pre-injection incubation time has little or
no effect on the hypoxia-specific tracer uptake in tumor
tissue. Thus, different oxygen breathing protocols clearly
confirmed that [
18F]FAZA is an appropriate PET bio-
marker for in vivo analysis of hypoxia, especially for late
measurements.
Additional material
Additional file 1: Tracer synthesis and cell culture conditions of
CT26 mouse colon carcinoma cells. In additional file 1, we have listed
a detailed description of all radiotracer synthesis ([
18F]FAZA and [
18F]FDG)
along with the exact cell culture conditions of CT26 mouse colon
carcinoma cells.
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